Polycystic kidney disease is an inherited condition in which many fluid-filled cysts grow in the kidneys. Over time, the kidneys enlarge, healthy kidney tissue gets crowded, and kidney function can decline. Some people find out because a parent has the condition. Others discover it after high blood pressure, blood in the urine, kidney pain, or an imaging test done for another reason.
The most common adult form is autosomal dominant polycystic kidney disease, often shortened to ADPKD. It usually develops slowly, but early diagnosis matters because blood pressure control, risk assessment, family screening, and treatment choices can change the long-term plan. This article explains what early signs to watch for, how the genetics work, who should be screened, what tests doctors use, and what treatment usually involves.
Table of Contents
- What Polycystic Kidney Disease Means
- Early Signs and Symptoms
- Genetics and Family Risk
- Screening and Diagnosis
- Predicting Progression
- Treatment and Monitoring
- Complications Outside the Kidneys
- Practical Next Steps
What Polycystic Kidney Disease Means
Polycystic kidney disease means the kidneys develop many cysts. A kidney cyst is a round, fluid-filled sac. One or two simple cysts become more common with age and usually do not mean PKD. In PKD, the pattern is different: cysts develop in both kidneys, grow over time, and are linked to an inherited change in genes that help kidney tubules develop and function.
The adult form, ADPKD, is the main focus of most discussions because it is the most common inherited kidney disorder. Cysts often start forming years before symptoms appear. A person in their 20s or 30s can have enlarged kidneys and high blood pressure while still having normal creatinine and eGFR. That is why a normal kidney blood test does not always rule out early ADPKD.
There is also a rarer childhood form called autosomal recessive polycystic kidney disease, or ARPKD. It usually appears before birth, in infancy, or during childhood and also affects the liver. ARPKD has a different inheritance pattern and a different care pathway. When adults say “PKD,” they usually mean ADPKD unless the context is a child with early severe disease.
PKD is not the same as having a single cyst, a complex cyst, or a few age-related cysts found on ultrasound. If an imaging report mentions cysts, the next question is pattern: how many, on one kidney or both, at what age, and with what family history. A report showing multiple cysts in both kidneys in someone with an affected parent is much more suggestive than one small cyst in a 70-year-old.
For a broader explanation of cyst types and follow-up terms, see kidney cysts.
Early Signs and Symptoms
The earliest clue is often high blood pressure before kidney function looks abnormal. ADPKD changes kidney structure and blood flow, which activates blood pressure systems inside the body. A young adult with repeated readings above the normal range, especially with a parent who has PKD, deserves a kidney-focused evaluation rather than years of “watching it.”
Many people have no symptoms at first. Others notice vague back, side, or abdominal discomfort as the kidneys enlarge. The pain is usually felt in the flank, which is the area between the lower ribs and the hips. A sudden sharp pain is different and raises concern for cyst bleeding, a kidney stone, infection, or another urgent problem.
Common early or developing signs include:
| Sign or symptom | What it can mean in PKD | What to do next |
|---|---|---|
| High blood pressure | Often appears before major kidney function loss | Check repeated home or clinic readings and ask about kidney testing |
| Flank or back pain | Enlarged kidneys, cyst pressure, cyst bleeding, stones, or infection | Seek care quickly if pain is severe, sudden, or paired with fever |
| Blood in urine | Cyst bleeding, stones, infection, or another urinary tract problem | Get urine testing, especially if urine is red, tea-colored, or has clots |
| Frequent UTIs | Bladder infection, kidney infection, or rarely an infected cyst | Culture the urine and review symptoms with a clinician |
| Kidney stones | Stones occur more often in people with distorted kidney anatomy | Ask whether imaging, stone analysis, or prevention testing is needed |
| Rising creatinine or low eGFR | Loss of filtering function, often later than cyst growth | Follow trends over time rather than one isolated number |
Blood in the urine should not be brushed off as “just PKD.” Even when cyst bleeding is likely, doctors still look for infection, stones, and other causes. A short episode after heavy activity or minor cyst bleeding often clears, but persistent visible blood, clots, severe pain, or fever needs prompt evaluation. A full guide to warning signs is covered in blood in urine.
Swollen ankles, puffy eyes, nausea, poor appetite, itching, fatigue, and shortness of breath usually point to more advanced kidney disease or another medical problem. They are not the usual first signs of ADPKD, but they matter if they appear. No urine, very low urine output, confusion, chest pain, or severe shortness of breath is urgent.
Genetics and Family Risk
ADPKD is usually inherited in an autosomal dominant pattern. That means a person with an ADPKD-causing gene change has a 50% chance of passing it to each child. The condition affects all sexes and can appear in every generation of a family.
The two best-known genes are PKD1 and PKD2. PKD1-related disease is more common and, on average, progresses faster. PKD2-related disease often progresses more slowly, with kidney failure later in life or sometimes not at all. This is a pattern, not a guarantee. Two relatives with the same gene change can still have different blood pressure patterns, cyst growth, pain, liver cyst burden, and kidney function over time.
Doctors now recognize a wider ADPKD spectrum. Some families have changes in other genes linked with kidney and liver cysts, such as GANAB, DNAJB11, ALG5, ALG9, or IFT140. These can look milder, atypical, or confusing on imaging. This matters because a person with “not quite classic” cyst patterns still deserves a careful family and genetic review when the story fits.
About 10% to 20% of people diagnosed with ADPKD do not have a clearly affected parent. Reasons include a new gene change, a parent who had mild undiagnosed disease, limited family information, adoption, early death of a parent, or mosaicism, where the genetic change is present in only some cells.
Genetic testing is not needed for every person with a classic family history and clear imaging. It becomes more useful when the diagnosis is uncertain, imaging is unclear because the person is young, there is no known family history, a potential living kidney donor is related to someone with ADPKD, or a couple wants reproductive options such as preimplantation genetic testing.
A negative genetic test does not always erase suspicion. PKD1 is technically difficult to test, and not every disease-causing variant is easy to detect. The best testing strategy uses a kidney genetics panel interpreted by clinicians who understand cystic kidney disease, not a single-gene shortcut chosen without context.
Screening and Diagnosis
Screening is usually considered when someone has a parent, sibling, or child with ADPKD. The goal is not just to “find cysts.” The goal is to confirm or rule out the condition as accurately as possible for that person’s age, start blood pressure monitoring, identify complications early, and support life decisions such as family planning, insurance planning, and possible kidney donation.
Ultrasound is often the first imaging test. It is widely available, does not use radiation, and usually shows whether both kidneys have multiple cysts. Ultrasound is strongest when the person is older and the family’s ADPKD pattern is known. In younger adults, especially those from milder PKD2 families, a normal ultrasound does not always fully exclude the condition.
MRI gives more detail and is useful when doctors need to measure total kidney volume, estimate progression risk, or clarify an uncertain ultrasound. CT also shows cysts well, but it uses radiation and sometimes contrast dye, so it is not the default screening choice for everyone. A comparison of common imaging choices is explained in kidney ultrasound vs CT scan.
Testing usually includes more than imaging:
- Blood pressure measurement, ideally with repeated home readings or ambulatory monitoring when results are borderline.
- Blood tests for creatinine and eGFR to estimate filtering function.
- Urine testing for blood, albumin, or protein.
- Review of family history, including kidney failure, dialysis, transplant, brain aneurysm, sudden unexplained death, and liver cyst disease.
- Genetic counseling or testing when imaging and family history do not give a clear answer.
Children in ADPKD families need a thoughtful approach. Some families choose early testing because high blood pressure can start in childhood and should be treated. Others prefer monitoring blood pressure and urine without confirming genetic status until the child is old enough to participate in the decision. The right choice should involve a pediatric kidney specialist when possible, especially if a child has high blood pressure, blood in the urine, enlarged kidneys, or a family history of severe early disease.
Adults who are considering donating a kidney to an affected relative need very clear exclusion of ADPKD. A related donor with even mild undiagnosed disease faces personal risk and is not an appropriate donor until the evaluation is settled.
Predicting Progression
Two people with ADPKD can have very different futures. One person needs dialysis or a transplant in their 50s. Another keeps enough kidney function into their 70s or beyond. Prognosis is not based on cyst count alone. Doctors look at kidney size, age, eGFR trends, gene information when available, blood pressure, sex, early symptoms, and family history.
Total kidney volume is one of the most useful predictors. In ADPKD, kidney enlargement often happens before eGFR drops. A person can have a normal eGFR but very large kidneys for their height and age, which signals faster progression. MRI is commonly used when accurate kidney volume is needed.
The Mayo Imaging Classification groups typical ADPKD into classes based on height-adjusted kidney volume and age. Classes 1C, 1D, and 1E generally suggest a faster course than 1A or 1B. This classification helps identify people most likely to benefit from disease-modifying treatment, especially tolvaptan.
The PROPKD score is another tool. It uses factors such as sex, early high blood pressure, early urologic symptoms, and genotype. It is most helpful when genetic information is available and the person already has enough clinical history to score meaningfully.
eGFR trends still matter. A single eGFR reading is a snapshot. The slope over several years shows whether kidney function is stable or falling. A steady decline, especially when paired with large kidneys for age, points to higher risk. For help understanding eGFR results, see low eGFR.
Urine albumin or protein is also useful. Heavy protein in the urine is not typical for uncomplicated ADPKD and can signal another kidney problem on top of PKD. Mild albumin elevation is more common and still deserves attention because it often tracks with kidney and blood pressure risk. The meaning of albumin testing is explained in albumin in urine.
Treatment and Monitoring
ADPKD treatment has two goals: slow kidney damage and manage complications quickly. The plan should be active even when symptoms are mild. Waiting until eGFR drops misses the years when blood pressure control, risk prediction, and treatment decisions are most useful.
Blood pressure control is the foundation. Many people with ADPKD develop high blood pressure early, and treating it protects the kidneys, heart, and brain. ACE inhibitors or ARBs are commonly used because they target the renin-angiotensin system, which is often activated in ADPKD. These medicines require monitoring of creatinine and potassium after starting or changing the dose. For a deeper explanation, see ACE inhibitors and kidney protection.
Diet and lifestyle changes are practical, not cosmetic. The most important habits are reducing sodium, avoiding smoking, maintaining a healthy weight, staying physically active, and using pain medicines safely. Long-term or frequent NSAID use, such as ibuprofen or naproxen, can add kidney risk, especially when kidney function is already reduced or dehydration is present.
Tolvaptan is the main disease-modifying medication for adults with ADPKD who are at high risk of rapid progression. It blocks vasopressin V2 receptors, which helps slow cyst growth and kidney function decline in selected patients. It is not for everyone. Doctors usually consider age, eGFR, kidney size, rate of decline, Mayo class, symptoms, and personal priorities before recommending it.
Tolvaptan causes predictable water-related side effects because it makes the kidneys release more free water. People often urinate more, wake at night to urinate, feel thirstier, and need reliable access to water and bathrooms. Liver blood tests are required because rare but serious liver injury can occur. A person who cannot manage the urination burden, follow monitoring, or safely maintain fluid intake may need a different plan.
Pain management should be specific to the cause. Dull chronic discomfort from large kidneys is treated differently from a stone, cyst infection, muscle strain, or cyst bleeding. Sudden severe flank pain with fever needs urgent evaluation. Repeated pain episodes deserve imaging review and a plan rather than repeated short-term pain prescriptions.
Kidney failure planning should start before crisis. When eGFR falls into advanced chronic kidney disease ranges, the care team should discuss transplant referral, dialysis education, access planning, anemia, bone and mineral labs, vaccines, and medication adjustments. Transplant is often a strong option for eligible people with ADPKD, and many do well after transplant. For a practical overview, see kidney transplant basics.
Complications Outside the Kidneys
ADPKD is a whole-body condition, not only a kidney cyst condition. The most common extra-kidney finding is liver cysts. Many people have liver cysts and never develop liver failure. The liver usually continues to work, but cyst burden can cause abdominal fullness, early satiety, reflux, shortness of breath when lying flat, or discomfort from a large liver.
Liver cyst burden is often greater in women and can be influenced by estrogen exposure, including multiple pregnancies or some hormone therapies. Treatment is only needed when symptoms are significant. Options depend on cyst pattern and include targeted cyst drainage, fenestration, liver-directed procedures, or in rare severe cases, transplant evaluation.
Brain aneurysm risk is higher in ADPKD than in the general population, but routine screening for every person is not always the best approach. Screening is more strongly considered when there is a personal history of aneurysm, a family history of aneurysm or subarachnoid hemorrhage, a high-risk occupation where sudden loss of consciousness could endanger others, upcoming major surgery, or strong anxiety after counseling. Magnetic resonance angiography is commonly used when screening is chosen.
A sudden “worst headache,” headache with stiff neck, fainting, weakness on one side, new confusion, seizure, or vision change is an emergency. That warning applies to everyone, but it is especially important for someone with ADPKD and aneurysm risk factors.
Heart valve changes, enlarged aortic root, abdominal wall hernias, pancreatic cysts, diverticular disease, kidney stones, and cyst infections also occur more often in ADPKD than in the general population. Not everyone needs screening for every possible complication. The care plan should match symptoms, family history, exam findings, and planned procedures.
Pregnancy needs early planning. Many people with ADPKD have healthy pregnancies, especially with normal kidney function and controlled blood pressure before conception. Risk rises with high blood pressure, reduced eGFR, significant protein in urine, or prior preeclampsia. Medication review matters because ACE inhibitors, ARBs, tolvaptan, and some other drugs are not used during pregnancy.
Practical Next Steps
A person with possible ADPKD should not try to manage the question with scattered tests. The most useful next step is a focused kidney evaluation that connects symptoms, imaging, family history, blood pressure, and labs.
Use this checklist to prepare for an appointment:
- Write down which relatives had kidney cysts, dialysis, transplant, brain aneurysm, sudden severe headache, stroke at a young age, or unexplained early death.
- Bring copies of ultrasound, CT, or MRI reports, not just a verbal summary.
- Track home blood pressure for one to two weeks using a validated cuff.
- Ask for creatinine, eGFR, urinalysis, and urine albumin-to-creatinine ratio if they have not been checked recently.
- Ask whether kidney size or total kidney volume should be measured, especially if you are under 55 and might be at risk of rapid progression.
- Discuss whether genetic counseling is useful before genetic testing.
- Review medicines and supplements, including NSAIDs, decongestants, creatine, protein powders, and herbal products.
- Ask what symptoms should trigger urgent care.
A nephrologist is the right specialist for diagnosis, risk prediction, blood pressure strategy, tolvaptan decisions, and long-term kidney planning. A urologist is often involved for stones, obstruction, cyst procedures, persistent visible blood in urine, or certain pain problems. Many people need both at different points.
Consider a nephrology referral if imaging suggests multiple bilateral kidney cysts, a first-degree relative has ADPKD, blood pressure is high before age 35, eGFR is falling, urine protein is present, or kidney size is enlarged for age. Referral is also important before pregnancy planning, living kidney donation, or genetic testing that could affect relatives. More referral clues are covered in when to see a nephrologist.
The most common mistake is assuming nothing can be done because PKD is genetic. The genes cannot be changed, but the course of care can. Blood pressure control, sodium reduction, smoking avoidance, careful medication use, risk-based monitoring, timely tolvaptan decisions, and early transplant planning all change real outcomes.
References
- KDIGO 2025 Clinical Practice Guideline for the Evaluation, Management, and Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) 2025 (Guideline)
- KDIGO 2025 clinical practice guideline for the evaluation, management, and treatment of autosomal dominant polycystic kidney disease (ADPKD): executive summary 2025 (Guideline Summary)
- Autosomal dominant polycystic kidney disease: an overview of recent genetic and clinical advances 2025 (Review)
- Genetic testing in autosomal dominant polycystic kidney disease: why it matters in 2025 2025 (Review)
- Polycystic Kidney Disease, Autosomal Dominant 2022 (GeneReviews)
- An update on the use of tolvaptan for autosomal dominant polycystic kidney disease: consensus statement on behalf of the ERA Working Group on Inherited Kidney Disorders, the European Rare Kidney Disease Reference Network and Polycystic Kidney Disease International 2022 (Consensus Statement)
Disclaimer
This article is for education about polycystic kidney disease and does not diagnose ADPKD, estimate your personal kidney failure risk, or replace care from a qualified clinician. Screening choices, genetic testing, tolvaptan use, pregnancy planning, and kidney donation decisions should be made with a nephrologist or genetics professional who can review your imaging, labs, family history, and goals. Seek urgent medical care for severe flank pain, fever with urinary symptoms, visible blood with clots, very low urine output, or a sudden severe headache.
